文献速递泌尿男性生殖肿瘤

血浆肾损伤分子-1用于术前预测肾细胞癌与良性肾脏肿块及与临床结局的关联

Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes.
PubMed 文献 · J Clin Oncol · 2024-05-03

在兩個獨立隊列中評估術前血漿腎損傷分子-1(pKIM-1)鑑別腎細胞癌(RCC)與良性腎臟肿块及預測臨床結局的能力。隊列1(162例透明細胞RCC與162例良性肿块)中pKIM-1鑑別RCC的AUC-ROC為0.81(95%CI 0.76-0.86);隊列2(247例cT1a肿块,184例RCC)中AUC-ROC為0.74(95%CI 0.67-0.80),加入pKIM-1後模型AUC-ROC由0.65升至0.78。隊列1隨訪中較高pKIM-1與較差無轉移生存(HR 1.29)和總生存(HR 1.31)相關。

要点

  • pKIM-1可鑑別RCC與良性腎臟肿块,隊列1 AUC-ROC 0.81,隊列2(cT1a)AUC-ROC 0.74。
  • 隊列2中pKIM-1加入既有列線圖使AUC-ROC由0.65升至0.78。
  • 隊列1中較高pKIM-1與較差無轉移生存(HR 1.29)和總生存(HR 1.31)相關。

核心结论

  • 在腎臟肿块患者中,pKIM-1與惡性病理、較差無轉移生存和死亡風險相關。
  • pKIM-1可能有助於選擇腎臟肿块患者接受干預還是監測。

研究设计与样本

  • 在兩個獨立腎臟肿块患者隊列中測量腎切除術前pKIM-1。
  • 隊列1來自前瞻性K2試驗,包括162例透明細胞RCC(病例)和162例良性腎臟肿块(對照)。
  • 隊列2來自學術生物樣本庫,包括247例小(cT1a)腎臟肿块患者,其中184例為RCC。

主要发现

  • 隊列1中pKIM-1鑑別RCC與良性肿块的AUC-ROC為0.81(95%CI 0.76-0.86)。
  • 隊列2(僅cT1a)中pKIM-1鑑別RCC與良性肿块的AUC-ROC為0.74(95%CI 0.67-0.80)。
  • 隊列2中將pKIM-1加入既有惡性預測列線圖後模型AUC-ROC由0.65(95%CI 0.57-0.74)升至0.78(95%CI 0.72-0.85)。
  • 基於隊列2確定的pKIM-1切點在隊列1中鑑別RCC的敏感度為92.5%、特異度為60%。
  • 隊列1 RCC病例長期隨訪中,較高術前pKIM-1與較差無轉移生存(多變量MFS HR 1.29/log pKIM-1單位增加,95%CI 1.10-1.53)和總生存(多變量OS HR 1.31/log pKIM-1單位增加,95%CI 1.10-1.54)相關。

临床怎么用

  • 作者認為pKIM-1可能有助於選擇腎臟肿块患者接受干預還是監測。

局限性

  • 原文未報告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Both clear cell and papillary renal cell carcinomas (RCCs) overexpress kidney injury molecule-1 (KIM-1). We investigated whether plasma KIM-1 (pKIM-1) may be a useful risk stratification tool among patients with suspicious renal masses. METHODS: Prenephrectomy pKIM-1 was measured in two independent cohorts of patients with renal masses. Cohort 1, from the prospective K2 trial, included 162 patients found to have clear cell RCC (cases) and 162 patients with benign renal masses (controls). Cohort 2 included 247 patients with small (cT1a) renal masses from an academic biorepository, of whom 184 had RCC. We assessed the relationship between pKIM-1, surgical pathology, and clinical outcomes. RESULTS: In Cohort 1, pKIM-1 distinguished RCC versus benign masses with area under the receiver operating curve (AUC-ROC, 0.81 [95% CI, 0.76 to 0.86]). In Cohort 2 (cT1a only), pKIM-1 distinguished RCC versus benign masses (AUC-ROC, 0.74 [95% CI, 0.67 to 0.80]) and the addition of pKIM-1 to an established nomogram for predicting malignancy improved the model AUC-ROC (0.65 [95% CI, 0.57 to 0.74] v 0.78 [95% CI, 0.72 to 0.85]). A pKIM-1 cutpoint identified using Cohort 2 demonstrated sensitivity of 92.5% and specificity of 60% for identifying RCC in Cohort 1. In long-term follow-up of RCC cases (Cohort 1), higher prenephrectomy pKIM-1 was associated with worse metastasis-free survival (multivariable MFS hazard ratio [HR] 1.29 per unit increase in log pKIM-1, 95% CI, 1.10 to 1.53) and overall survival (multivariable OS HR 1.31 per unit increase in log pKIM-1, 95% CI, 1.10 to 1.54). In long-term follow-up of Cohort 2, no metastatic events occurred, consistent with the favorable prognosis of resected cT1a RCC. CONCLUSION: Among patients with renal masses, pKIM-1 is associated with malignant pathology, worse MFS, and risk of death. pKIM-1 may be useful for selecting patients with renal masses for intervention versus surveillance.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Xu W, Gaborieau V, Niman SM, et al. Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes. J Clin Oncol. 2024. PMID: 38701382. doi:10.1200/JCO.23.00699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。